News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
251,029 Results
Type
Article (6787)
Company Profile (26)
Press Release (244216)
Section
Business (89095)
Career Advice (592)
Deals (16628)
Drug Delivery (9)
Drug Development (22852)
Employer Resources (43)
FDA (4402)
Job Trends (4772)
News (133625)
Policy (9102)
Tag
Academia (409)
Alliances (16610)
Alzheimer's disease (317)
Approvals (4406)
Artificial intelligence (33)
Bankruptcy (107)
Best Places to Work (3602)
Biotechnology (31)
Breast cancer (58)
Cancer (389)
Career advice (503)
Cell therapy (82)
Clinical research (18885)
Collaboration (140)
Compensation (104)
COVID-19 (526)
C-suite (63)
Data (456)
Diabetes (40)
Diagnostics (2284)
Earnings (42427)
Employer resources (43)
Events (40996)
Executive appointments (216)
FDA (4607)
Funding (162)
Gene therapy (35)
GLP-1 (122)
Government (686)
Healthcare (5924)
Infectious disease (542)
Interviews (99)
IPO (8405)
Job creations (1275)
Job search strategy (435)
Layoffs (106)
Legal (2725)
Lung cancer (38)
Manufacturing (43)
Medical device (4484)
Medtech (4486)
Mergers & acquisitions (8344)
Metabolic disorders (111)
Neuroscience (416)
NextGen: Class of 2025 (1945)
Non-profit (909)
Northern California (711)
Obesity (57)
Opinion (40)
People (26508)
Phase I (5459)
Phase II (8339)
Phase III (6563)
Pipeline (322)
Postmarket research (756)
Preclinical (2196)
Press Release (67)
Radiopharmaceuticals (118)
Rare diseases (60)
Real estate (2055)
Regulatory (6033)
Research institute (405)
Resumes & cover letters (74)
Southern California (520)
Startups (1161)
United States (5868)
Vaccines (52)
Date
Today (34)
Last 7 days (322)
Last 30 days (772)
Last 365 days (12875)
2025 (511)
2024 (12986)
2023 (15253)
2022 (21293)
2021 (22651)
2020 (20415)
2019 (15122)
2018 (11597)
2017 (11278)
2016 (10384)
2015 (13601)
2014 (10677)
2013 (8581)
2012 (9344)
2011 (9662)
2010 (9480)
Location
Africa (215)
Arizona (56)
Asia (12434)
Australia (1801)
California (1453)
Canada (915)
China (49)
Colorado (68)
Connecticut (78)
Europe (26593)
Florida (217)
Georgia (32)
Idaho (29)
Illinois (93)
Indiana (66)
Japan (47)
Kansas (58)
Maine (36)
Maryland (166)
Massachusetts (1221)
Michigan (87)
Minnesota (125)
New Jersey (527)
New York (422)
North Carolina (307)
Northern California (711)
Ohio (42)
Pennsylvania (338)
South America (333)
Southern California (520)
Texas (203)
Utah (42)
Washington State (123)
251,029 Results for "anx robotica corp".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
AnX Robotica Announces FDA Clearance for ProScan™: A Groundbreaking AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy
AnX Robotica, a pioneering force in advanced gastrointestinal visualization technologies, is excited to announce the FDA clearance of NaviCam ProScan™.
January 3, 2024
·
2 min read
Policy
AnX Robotica is Pleased to Announce FDA Clearance for Expanded Indications of NaviCam Small Bowel Video Capsule Endoscopy
AnX Robotica is thrilled to announce FDA clearance for expanded indications of its NaviCam Small Bowel Video Capsule Endoscopy in both adults and children aged 2 years and above.
January 15, 2024
·
2 min read
Lone Star Bio
AnX Robotica Commences Launch of the NaviCam® Small Bowel System
AnX Robotica Corporation (www.anxrobotics.com), the developer and manufacturer of the NaviCam® Magnetically Controlled Capsule Endoscopy System (MCCE), is pleased to announce the launch of the NaviCam Small Bowel System in the United States.
February 6, 2023
·
1 min read
Business
AnX Robotica Partners with GastroGPO, a Specialty Networks Company
AnX Robotica Corporation, the developer and manufacturer of the NaviCam® Magnetically Controlled Capsule Endoscopy System, is pleased to announce a partnership with GastroGPO, a Specialty Networks Company.
December 7, 2022
·
2 min read
Press Releases
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
December 6, 2024
·
9 min read
Drug Development
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting
Annexon, Inc. (Nasdaq: ANNX), today announced positive results from the completed pivotal Phase 3 trial of C1q-targeted immunotherapy, ANX005, in Guillain-Barré Syndrome (GBS) at the 2024 Peripheral Nerve Society (PNS) Annual Meeting in Montréal, Canada.
June 25, 2024
·
9 min read
Biotech Bay
Annexon To Present Pivotal Phase 3 Data On Early And Durable Benefits With First-In-Class C1q Blocking Antibody ANX005 In Guillain-Barré Syndrome At 2024 PNS Annual Meeting
Annexon, Inc. today announced the Company will have several presentations on the Company’s ANX005 Guillain-Barré Syndrome (GBS) program at the 2024 Peripheral Nerve Society (PNS) Annual Meeting being held June 22-25, 2024 at the Palais des congrès de Montréal in Montréal, Canada.
June 18, 2024
·
7 min read
Press Releases
Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)
December 16, 2024
·
12 min read
Drug Development
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
Annexon, Inc. (Nasdaq: ANNX) today presented new analyses of ANX007 from the Phase 2 ARCHER trial in geographic atrophy (GA), and new preclinical data on the role of C1q in the pathogenic elimination of photoreceptor synapses and their protection with C1q blockade in GA.
May 7, 2024
·
11 min read
Press Releases
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
October 15, 2024
·
7 min read
1 of 25,103
Next
